Annexin II heterotetramer (AIIt) is a Ca 2+ -and phospholipid-binding protein that consists of two copies of a p36 and p11 subunit. AIIt regulates the production and autoproteolysis of plasmin at the cell surface. In addition to its role as a key cellular protease, Cys 82 -Ser inactivated the plasmin reductase activity of the isolated subunits, suggesting that specific cysteinyl residues participated in the plasmin reductase activity of each subunit.
Introduction
Angiostatin was originally identified in the urine of mice bearing Lewis lung carcinoma (LLC) as a 38 kDa proteolytically-derived fragment of plasminogen which encompassed the first four kringle domains (Lys 78 -Ala 440 ). Angiostatin was shown to be a potent antiangiogenic protein that inhibited the growth of human and murine carcinomas and also induced dormancy in their metastases. Angiostatin was also characterized as a specific antiangiogenic protein that blocked microvascular endothelial cell proliferation but not the proliferation of nonendothelial cells (1) .
It is now apparent that angiostatin is a member of a family of anti-angiogenic plasminogen fragments (AAPFs). Physiologically relevant AAPFs include a 38 kDa AAPF isolated from the conditioned media of tumor-infiltrating macrophages (2), a 43 kDa and 38 kDa AAPF identified in the conditioned media of Chinese hamster ovary and HT1080 fibrosarcoma cells and a 48 kDa AAPF present in macrophage conditioned media (3) . Other AAPFs include a 43 kDa and a 38 kDa AAPF isolated from the conditioned media of human prostrate carcinoma PC-3 cells (4;5) and AAPFs of 66, 60 and 57 kDa detected in the conditioned media of HT1080 and Chinese hamster ovary cells (6) . Since the carboxyl-terminus of most of these AAPFs was not determined, the exact primary sequence of most of the AAPFs is not known.
Two distinct pathways have been identified for the formation of AAPFs. First, certain proteinases can directly cleave plasminogen into AAPFs. These proteinases include metalloelastase, gelatinase B (MMP-9), stromelysin-1 (MMP-3), matrilysin (MMP-7), cathepsin D and prostate-specific antigen (7) (8) (9) (10) (11) . The source of these proteinases may be tumorinfiltrating macrophages (2) or the cancer cells themselves. For example, the conversion of plasminogen to angiostatin by macrophages is dependent on the release of metalloelastase from these cells. In comparison, Lewis lung carcinoma cells release MMP-2 which also cleaves plasminogen to angiostatin (12) . Second, AAPFs are also generated by a three step mechanism which involves the conversion of plasminogen to plasmin by urokinase type plasminogen activator (u-PA), the autoproteolytic cleavage of plasmin and the release of the resultant plasmin fragment by cleavage of disulfide bonds. The cleavage of the plasmin disulfide bonds can be accomplished by free sulfhydryl group donors (FSD) such as glutathione or by hydroxyl ions at alkaline pH (4;5;13;14) .
Alternatively, the plasmin disulfide bonds can be cleaved enzymatically by a plasmin reductase such as phosphoglycerate kinase (15;16) .
Our laboratory has shown that the primary AAPF present in mouse and human blood has a molecular weight of 61 kDa (14) . We have produced this AAPF, called A 61 , in a cell-free system consisting of u-PA and plasminogen. A 61 was shown to be a novel four-kringle containing plasminogen fragment consisting of the amino acid sequence, Lys 78 -Lys 468 (14) . The release of A 61 from plasmin required cleavage of the Lys 468 -Gly 469 bond by plasmin autoproteolysis and also cleavage of the Cys 462 -Cys 541 disulfide. Since A 61 was generated in our cell-free system from plasmin at alkaline pH in the absence of sulfhydryl donors, we concluded that cleavage of the Cys 462 -Cys 541 disulfide was catalyzed by hydroxyl ions in vitro. In contrast, at physiological pH, we observed that the conversion of plasminogen to A 61 was very slow. These results contrasted with our observation that at physiological pH, HT1080 fibrosarcoma and bovine capillary endothelial (BCE) cells stimulated the rapid formation of A 61 . The mechanism by which these cells stimulated plasmin reduction and the release of A 61 from plasmin was unclear, however it was reasonable to suspect that the cells utilized a plasminogen-binding protein on the cell surface to facilitate the formation of A 61 .
Annexin II tetramer (AIIt) is a Ca 2+ -binding protein that binds plasminogen and plasmin and stimulates both the formation and autoproteolysis of plasmin at the cell surface (17) (18) (19) (reviewed in (20) ). The protein consists of two copies of a 36 kDa subunit (p36) called annexin II and two copies of a 11 kDa subunit (p11) called S100A10. Previous work from our laboratory has shown that the carboxyl-terminal lysines of the p11 subunit play a key role in plasminogen binding and activation (18) .
In the present report we show that AIIt stimulates the conversion of plasminogen to A 61 in vitro. We also report for the first time that AIIt possesses an intrinsic plasmin reductase activity, and that the cysteinyl residues of both subunits of AIIt participate in the reduction of plasmin. Among the seven annexins tested, only annexin II (p36) and AIIt act as plasmin reductase. Additionally, the antisense nucleotide-directed down-regulation of AIIt on the surface of HT1080 fibrosarcoma cells, greatly diminishes A 61 production by these cancer cells.
Our results therefore show for the first time that AIIt may play a role in angiogenesis by regulating the cellular release of an antiangiogenic protein.
EXPERIMENTAL PROCEDURES
Materials -Two-chain urokinase-type plasminogen activator (u-PA) was a generous gift from Dr. H. Stack (Abbott Laboratories).
[Glu]-plasminogen and plasmin were purchased from American Diagnostica. Antiangiogenic plasminogen fragment (A 61 ) was purified as outlined previously (14) . Annexin II tetramer (AIIt) and other annexins were purified from bovine lung as described in (21) . Monoclonal anti-human plasminogen kringle 1-3 antibody was purchased from Enzyme Research Laboratories Inc. Monoclonal anti-annexin II and anti-annexin II light chain antibodies were purchased from Transduction Laboratories. Anti-mouse horseradish peroxidase-conjugated secondary antibody was purchased from Santa Cruz Biotechnology.
Horseradish peroxidase-conjugated streptavidin and protein disulfide isomerase were purchased from Calbiochem. Anti-mouse R-phycoerythrin-conjugated secondary antibody was purchased from Caltag Laboratories Inc. N α -(3-maleimidylpropionyl)biocytin (MPB) was purchased from protease inhibitors) and centrifuged at 100,000 x g for 1 hour at 4 °C. Both mutant annexin II proteins were purified in the same manner as wild-type annexin II via hydroxyapatite, heparinSepharose affinity and gel permeation chromatography as reported previously (22) . The elution profiles of the recombinant wild-type and mutant annexin II on hydroxyapatite, heparin affinity and gel permeation chromatography were indistinguishable. In addition, the circular dichroism spectra of each of the proteins were very similar, indicating little secondary structure perturbation.
Purification of Wild-type and Mutant p11 -After 4 hours of induction with IPTG, bacteria were collected by low speed centrifugation. The cells were subsequently sonicated in lysis buffer (100 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10 mM MgCl 2 , 2 mM DTT + protease inhibitors) and centrifuged at 100,000 x g for 1 h at 4 °C. Both p11 mutants were purified in the same manner as wild-type p11 (23) . Briefly, the cell lysis supernatant was precipitated with 50%
(NH 4 ) 2 SO 4 , and the supernatant was applied to a Butyl-Sepharose column equilibrated in lysis buffer containing 50% (NH 4 ) 2 SO 4 . The p11 was eluted with a linear gradient of (NH 4 ) 2 SO 4 from 50% to 0%, and peak fractions containing p11 were pooled and dialyzed against 10 mM imidazole, pH 7.4, 1 mM EGTA, 0.5 mM DTT, and 0.1 mM EDTA. The dialyzed fractions were subsequently applied to a DEAE-Sepharose column equilibrated in the same buffer. The p11
was eluted with a linear NaCl gradient, concentrated to 4 mL, and applied to a Sephacryl S-100 column equilibrated in 40 mM Tris-HCl, pH 7.4, 0.1 mM EGTA, and 0.1 mM DTT. A single protein peak was recovered at the expected molecular weight based on gel filtration standards.
Plasmid Construction and Transfection of HT1080 Cells -Sense and antisense p11 expression vector were produced by cloning the full-length human p11 cDNA into the pLin retroviral vector in the sense (pLin-p11S) or antisense orientation (pLin-p11AS) as reported (24) . 
Dialysis of Candidate Plasmin Reductase Proteins -After purification or reconstitution,
AIIt, p11, p36 (annexin II), other annexins, thioredoxin, protein disulfide isomerase, and phosphoglycerate kinase were dialyzed against 20 mM Tris (pH 7.5) and 140 mM NaCl under argon gas to prevent possible oxidation.
Plasmin Reductase Assay -[Glu]-plasminogen (4 µM) was incubated with 0.075 µM u-PA and a candidate plasmin reductase protein (4 µM, unless described) in a buffer containing 20 mM Tris (pH 7.5) and 140 mM NaCl at 37 °C for 2h. A portion of reaction mixture was diluted with SDS-PAGE sample buffer and subjected to non-reduced SDS-PAGE followed by
Coomassie blue staining. To label any free thiol groups of produced protein(s), the reaction mixture was incubated with 100 µM MPB at room temperature for 30 min. The reaction mixture was then treated with 200 µM reduced glutathione at room temperature for 10 min to quench the unreacted MPB. The unreacted glutathione and other free thiols in the reaction mixture were blocked with 400 µM of iodoacetamide at room temperature for 10 min. Then the reaction mixture was incubated with L-lysine-Sepharose at room temperature for 30 min to purify the kringle-containing, plasminogen-derived proteins. The matrix was extensively washed with PBS and the bound proteins were eluted by boiling the resin with SDS-PAGE sample buffer.
Each sample was subjected to non-reduced SDS-PAGE followed by Western blot with horseradish peroxidase-conjugated streptavidin (streptavidin-HRP) as indicated below.
Detection of free thiols in AIIt -2 µM AIIt, p11, or p36 was incubated with 100 µM MPB in a buffer containing 20 mM Tris (pH 7.5) and 140 mM NaCl at room temperature for 30 min. After incubation, 200 µM reduced glutathione and 400 µM iodoacetamide were added sequentially, and the reaction mixture was subjected to reduced SDS-PAGE followed by either
Coomassie blue staining or Western blot with streptavidin-HRP as indicated below. As shown in Fig. 1A (lane 2), the incubation of u-PA with plasminogen resulted in the generation of plasmin. As expected, the plasmin generated by this reaction did not contain a free cysteinyl residue and therefore did not react with MPB (Fig. 1B, lane 2) . However, the addition of AIIt to the u-PA-plasminogen reaction resulted in the appearance of A 61 (which displays a (Fig. 1A) . Furthermore, the A 61 generated in these reactions reacted with MPB, confirming the presence of a free sulfhydryl in A 61 (Fig. 1B) .
Cell-Mediated Generation of

Results
AIIt stimulates the conversion of plasminogen to
AIIt stimulated the dose-and time-dependent conversion of plasminogen to A 61 (Fig. 1A-D ). The maximal conversion of plasminogen to A 61 occurred at approximately equimolar concentrations of AIIt and plasminogen (Fig. 1A,B) . At equimolar concentrations the halfmaximal conversion of plasminogen to A 61 occurred between 30-60 min (Fig. 1C,D Role of the p36 and p11 subunits in the plasmin reductase activity of AIIt -AIIt is composed of two copies of a p36 and two copies of a p11 subunit. The p11 subunit plays a key role in plasminogen binding and stimulation of the plasminogen activator-catalyzed conversion of plasminogen to plasmin (18) . We therefore attempted to identify which subunit of AIIt was responsible for the plasmin reductase activity of AIIt. As shown in Fig. 2A ,B the incubation of either the p36 or p11 subunit with u-PA and plasminogen stimulated the formation of A 61 .
However, AIIt was a more potent plasmin reductase than either subunit, suggesting that the interaction of the subunits potentiated the plasmin reductase activity of either subunit.
Theoretically, either the disulfides or cysteinyl residues of AIIt could participate in the reduction of plasmin. It is possible that upon plasmin(ogen) binding the disulfide of annexin II is reduced by the thiols of annexin II and the newly formed thiols participate in reduction of plasmin. Since the p11 subunit does not contain disulfides we suspected that the thiols of this subunit were important for its plasmin reductase activity. p11 contains two cysteinyl residues:
Cys 61 which plays a critical role in the binding of p36 and Cys 82 which is a free thiol (25) . We prepared two recombinant forms of this subunit in which individual cysteinyl residues were mutated to serine. This conservative mutation results in the substitution of a thiol group for a hydroxyl group. As shown in Fig. 2B , substitution of either of these cysteine residues resulted in a loss of plasmin reductase activity of the p11 subunit. This suggests that both cysteinyl residues of p11 are required to sustain the plasmin reductase activity of the protein.
Human p36 contains two thiol-containing cysteines, Cys 8 and Cys 334 . As shown in Fig.   2B , substitution of Cys 334 , but not Cys 8 , with serine blocked the plasmin reductase activity of p36. This result suggests that the Cys 334 thiol is critical for plasmin reductase activity of the p36 subunit.
Thiol reactivity of AIIt and its subunits -In order to identify the reactive thiols of AIIt we
incubated AIIt and its individual subunits with MPB and resolved the mixture with SDS-PAGE followed by Coomassie blue staining (Fig. 3A) or Western blot with streptavidin-HRP (Fig. 3B ).
As shown in Fig. 3B (Fig. 3C ). This suggests that the Cys 334 thiol of the p36 subunit of AIIt is inaccessible to the solvent.
Specificity of the plasmin reductase activity of AIIt -The Cys 334 residue is highly conserved among many of the annexins. Since our data suggested that this residue participated in the plasmin reductase activity of p36, we suspected that other annexins which possess this cysteine might also have plasmin reductase activity. We therefore examined seven different annexins for plasmin reductase activity. As shown in Fig. 4 , only annexin II (p36) and AIIt possessed plasmin reductase activity. This result establishes that plasmin reductase activity is not a common feature of the annexins.
A 61 binds to AIIt -Previous data from our laboratory have established that AIIt binds both plasminogen and plasmin and is present at discrete regions of the extracellular surface (17;20;26) . This suggested that AIIt could act as a scaffolding protein and focus the proteolytic activity of plasmin to the plasma membrane. It was unclear if the A 61 generated by cells could remain bound to AIIt at the cell surface or be immediately released into the media. However, as shown in Previously, we demonstrated that AIIt was localized to the extracellular surface of a variety of cultured cells including human umbilical vein endothelial cells, BT20 breast carcinoma cells, U87 glioma and HT1080 fibrosarcoma cells (17;20;26) . Our in vitro studies established that AIIt and specifically its p11 subunit stimulated tPA-and u-PA-catalyzed conversion of plasminogen to plasmin (17;18;20) . Additional studies showed that AIIt stimulated plasmin autoproteolysis (19) . Most recently we demonstrated that HT1080 fibrosarcoma or bovine capillary endothelial cells converted plasminogen into the antiangiogenic plasminogen fragment, A 61 (14) . The current study has consolidated our previous studies by demonstrating that AIIt stimulates the formation of A 61 from plasminogen.
Our results also allow the development of a model to define the mechanism by which The mechanism by which oxidized extracellular AIIt is reduced is unknown at this time.
Our data indicate that both the p36 and p11 subunits of AIIt possess plasmin reductase activity. In the case of the p36 subunit the Cys 334 residue is essential for plasmin reductase activity. In the case of the p11 subunit both Cys 61 and Cys 82 are capable of participating in plasmin reduction. Although speculative, the simplest explanation for these results is that plasmin and autoproteolyzed plasmin can bind to AIIt but the unique conformational change induced by the binding of autoproteolyzed plasmin to AIIt results in increased accessibility of cysteinyl residues of AIIt which participate in reduction of autoproteolyzed plasmin. Since
Cys 334 of p36 is not labeled with the thiol specific reagent MPB it is likely shielded from the solvent.
Furthermore, the p36 Cys 334 -Ser mutant is inactive in terms of plasmin reductase activity. It is therefore reasonable to suspect that Cys 334 may be shielded and only accessible for reduction of plasmin upon binding of autoproteolyzed plasmin to AIIt.
Protein disulfide reductases typically contain the Cys-X-X-Cys motif in their active sites.
Members of this family of proteins include thioredoxin, protein disulfide isomerase, fibronectin, von Willebrand factor and platelet integrin α IIb β 3 (28;29;32-36) . Typically these proteins share the general property of catalyzing the reduction of insulin disulfides. In contrast, AIIt does not contain the Cys-X-X-Cys motif and does not catalyze the reduction of insulin disulfides. This suggests that the intrinsic plasmin reductase activity of AIIt is due to a novel mechanism of disulfide reduction.
Future studies will be directed towards defining the interactions that regulate the plasmin reductase activity of AIIt and determining how the subunits participate in this activity.
Acknowledgments
This work was supported by a grant from the National Institutes of Health (CA78639) and CIHR. 
